Novo-Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems; vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven(R) RT), growth hormone therapy, hormone replacement therapy and other products.